It is with deep sadness that we announce our dear friend and colleague Torsten Goesch passed away unexpectedly earlier this week. Torsten was a highly respected member of the Rosetta team and he is much missed. Our thoughts and condolences go out to Torsten's family during this difficult time.
Pharmaceutical
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company. It develops products and technology to improve the lives of transplant patients. The firm’s products and technology include Envarsus XR and meltdose technology. Veloxis was acquired by Asahi Kasei for $1.3 billion in 2019.
Location
Hørsholm, Denmark
History
Veloxis was acquired by Asahi Kasei for $1.3 billion in 2019
Registered in England No. 3941653 | VAT No. GB 765 3567 96
© 2017 Rosetta Capital Limited | Authorised and regulated by the Financial Conduct Authority
